Convalescent Plasma for COVID-19

Convalescent Plasma for the Treatment of Moderate-severe COVID-19: A Proof-of-principle Study

The purpose of this proof of concept study is to provide COVID-19 convalescent plasma to patients with moderate to severe COVID-19 and assess:

• the titer of anti-COVID-19 antibodies in the donors and in the patients before and after treatment;
• the in-depth analysis of immunological parameters in the donors and in recipient before and after treatment;
• the impact of plasma transfusion on the reduction of viral load and inflammation
• safety and tolerability
• clinical efficacy

Inclusion Criteria:

• Hospitalized adult patients 18 - 75 y.o. with confirmed COVID-19 infection by nasopharyngeal swab;
• radiologically confirmed pneumonia;
• SpO2 > 92o/o and < 96% (room air);
• ongoing thromboembolic prophylaxis.

Exclusion Criteria:

• Participation to another COVID-19 trial;
• severe COVID-19 disease (SpO2 < 93o/o in room air);
• severe allergic transfusion reactions or anaphylaxis in the patient history;
• documented lgA deficiency;
• unstable heart disease with signs of circulatory overload;
• malignancies or other concomitant diseases with poor short-term prognosis;
• pregnancy.